Market Research Blog – Page 6 – Just another WordPress site

Global Biosensors Market for Spectacular Growth, Projected to Reach US$ 65.2 Billion by 2033 at a 9.5% CAGR

The global biosensors market is expected to reach a size of about US$ 65.2 billion by 2033, signaling a considerable upswing in the industry. From US$24.5 billion in 2022, this represents a significant increase, demonstrating a strong compound annual growth rate (CAGR) of 9.5% for the anticipated period (2023-2033). The anticipated growth rate is higher than the previous growth rate, suggesting a phase of faster market expansion.

Biosensors are analytical tools that can detect a variety of materials, including glucose and enzymes, by converting biological impulses into electrical ones. They are essential to many applications in the food and beverage business, healthcare, and environmental monitoring.

The biosensors market is being driven by an increase in biotechnology research and development, the incidence of chronic illnesses like diabetes, and the necessity for homecare equipment. The increasing use of biosensors in glucose monitoring systems is driving the market’s growth. However, it is projected that market expansion will be hampered by opposition to adopting novel treatment devices and the high cost of these equipment. However, it is expected that developments in biosensor technology that promote mobility would drive market expansion.

Request Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16430

Biosensors based on nanotechnology are anticipated to yield significant profits in a range of sectors, such as food analysis, imaging, and microbiological activity monitoring. The market is getting more consolidated due to the growing need for non-invasive biosensors, customized medications, medical equipment, and more cooperation and agreements among producers in research.

Because of their ability to assess fitness as well as the onset and progression of illness, biosensors are widely used in home-based healthcare by patients. As a result, the market is expected to expand throughout the forecast period. A variety of non-medical activities, as well as technological advancement, are expected to broaden its applicability and, as a result, support its growth. Pregnancy testing, cholesterol testing, blood glucose testing, and drug detection are some of the healthcare services that are expected to have a positive market impact.

Government projects aimed at improving proteomics and genomics are expected to drive the biosensors market during the forecast period.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16430

Competitive Analysis

Because of the increased demand for biosensors, global manufacturers are accelerating and improving their manufacturing processes by implementing cost-effective solutions. A few of the key players in the biosensors market include Bio-Rad Laboratories Inc., Medtronic, Abbott Laboratories, Biosensors International Group, Ltd., Pinnacle Technologies Inc., Ercon, Inc., DuPont Biosensor Materials, Johnson & Johnson, Koninklijke Philips N.V., LifeScan, Inc., QTL Biodetection LLC, Molecular Devices Corp., Nova Biomedical, Molex LLC, TDK Corporation, Zimmer & Peacock AS, and Siemens Healthcare.

Some of the recent developments of key Biosensors providers are as follows:

In January 2022, Roche and Sysmex agreed to a Global Business Partnership (GBP) to provide haematological diagnostic services. The new collaboration will use IT technology to improve clinical decision-making and the consumer experience. This long-running, fruitful collaboration is still going strong, providing haematological diagnostic improvements to labs worldwide.
In December 2020, Abbott announced that FreeStyle Libre 2, its next-generation sensor-based glucose monitoring device, has been approved by Health Canada for adults and children (4 years and older) with diabetes.

Market Segments Covered in Biosensors Market Analysis

By Product Type:

Medical
- Cholesterol
- Blood Glucose
- Blood Gas Analyzer
- Pregnancy Testing
- Drug Discovery
- Infectious Disease
Food Toxicity
Bioreactor
Agriculture
Environment
Others

By Technology:

Thermal
Electrochemical
Piezoelectric
Optical

By End-Use:

Home Healthcare Diagnostics
PoC Testing
Food Industry
Research Laboratories
Security & Biodefense

By Region:

North America
Latin America
Europe
APAC
Middle East and Africa (MEA)

Detailed Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16430

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Klinefelter Syndrome Therapeutics Market Set to Flourish, Expected to Reach US$1.85 Billion by 2033 at a 5% CAGR

The Global Klinefelter Syndrome Therapeutics Industr for Klinefelter syndrome therapies will reach a worth of US$1.85 billion by 2033, indicating that the market is expected to develop at a substantial rate. The impressive US$1.14 billion in 2023 has significantly increased to this amount, indicating a compound annual growth rate (CAGR) of 5% throughout the anticipated period.

Males with Klinefelter syndrome are affected by a hereditary disorder that causes undeveloped testes, delayed puberty, and infertility, among other symptoms. Klinefelter syndrome now has no known cure; instead, care aims to control symptoms and enhance quality of life.

Due to the difficulty in diagnosing Klinefelter Syndrome due to its unknown symptoms, collaboration between the government and medical organizations such as the FDA and NIH has been established. Raising awareness of this ailment is intended to ensure early intervention and improve early detection.

The initiative is a part of bigger incentives for other health exams, which are anticipated to play a significant role in the market’s future expansion. Rising rates of male infertility and an increase in clinical symptoms across the board are expected to be the main drivers of market expansion.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16407

Europe is expected to be the second-fastest-growing region in the industry. The rising prevalence of the disease has enhanced research financing, and health organizations such as the National Institutes of Health (NIH) are focusing on raising awareness about the syndrome, which is cruising market growth. North America is expected to dominate the market due to the region’s large number of testosterone drugmakers, as well as increased awareness among the region’s population. In addition, a large number of treatment centers for this ailment will increase market share over the forecast period.

Key Takeaways from the Global Klinefelter Syndrome Therapeutics Industry Study

From 2018-2022, a CAGR of 4% was registered for the Klinefelter syndrome therapeutics market
By therapeutics, testosterone replacement therapy to experience maximum uptake, growing at a 3.1% CAGR
Hospital pharmacies to remain primary POC for availing Klinefelter syndrome therapeutics drugs, growing at a 4.6% CAGR
North America to emerge as the kingpin, registering a market share worth 38%
Europe to be the 2^ndlargest market, expected to accumulate a 34% revenue share
Asia Pacific to show significant growth, registering a CAGR of 5.1% until 2033

“With rising instances of male infertility, the need for seeking therapy and diagnostics to detect the presence of Klinefelter syndrome is increasing at a fast pace. Treatment providers are therefore endowed with an opportunity to introduce more robust approaches, generating many opportunities,” remarks an FMI analyst.

Key Market Players

Key players in the Klinefeltr Syndrome Therapeutics market are Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd, Pfizer Inc, AstraZeneca, AbbVie, Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company, GSK Plc, Novartis AG, Viatris.

Takeda Pharmaceutical Company Limited and Seagen Inc. announced that data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination would be conveyed verbally at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO).
In 2021, Pfizer Inc. launched Testosterone Cypionate Injection as a replacement therapy for males suffering from exogenously low testosterone or absence.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16407

Key Segments Profiled in the Global Klinefelter Syndrome Therapeutics Industry Report

By Therapeutics:

Testosterone Replacement Therapy
Fertility Treatment
Surgeries
Hormone Treatment
Others

By Application:

Hospitals
Specialty Clinics
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others

Explore In-Depth Market Research: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16407

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Durable Medical Equipment Rental Market for Remarkable Growth, Expected to Reach US$47 Billion by 2033 at a 5.7% CAGR

The Global Durable Medical Equipment Rental Market is expected to reach US$47 billion by 2033. From a market value of US$25.7 billion in 2022, this represents a stable growth trajectory, with a compound annual growth rate (CAGR) of 5.7% for the projected period (2023-2033).

The market for DME rentals provides patients with an affordable and practical means of obtaining the necessary medical equipment for their recuperation or long-term care requirements. This covers hospital beds, nebulizers, wheelchairs, walkers, and other equipment.

The broad use of the internet and the advancement of cutting-edge medical therapies are significantly altering the healthcare industry. With patients becoming more discerning and knowledgeable due to their easy access to a wealth of online information, there is an increasing demand for creative, cost-effective, and customized healthcare solutions. Hospitals are the main industry in this context that generates revenue, with a compound annual growth rate (CAGR) of more than 5.7% from 2023 to 2033.

The global healthcare system is experiencing unprecedented dynamics as a result of the COVID-19 pandemic. The pandemic has raised customer demand for healthcare products and services, which has improved industry performance as a whole. Because of this, the industry is growing quickly and the increase in demand has made it appealing for people to lease durable medical

Request a Sample of this Report Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16401

Despite the expected and exponential expansion, healthcare operators continue to struggle to find a long-term financing solution to invest in cutting-edge technology and equipment to fulfill the demands of an increasingly demanding consumer base. Renting medical equipment may be the next big thing in the global healthcare industry, offering cost-effective and economical solutions during difficult economic times.

The lack of uniform regulatory criteria for medical equipment rental services, as well as high costs, are projected to constrain the industry’s growth. Furthermore, it has been observed that few medical devices come with insurance, which will hinder the expansion of the global medical equipment rental sector.

In 2022, North America led the market. This is because of the country’s strong healthcare system and government support for privately operated hospitals, clinics, and diagnostic services.

Competitive Analysis

Some of the key players operating in the medical equipment rental market include Hill-Rom Holdings Inc., Stryker Corporation, Getinge AB, Siemens Financial Services Inc, Nunn’s Home Medical Equipment, Westside Medical Supply, Universal Hospital Services, Inc., Woodley Equipment Company Ltd., GE Healthcare, C.N.Y. Medical Products Inc., All American Medical Supply Corp., and Homepro Medical Supplies, LLC.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16401

Some of the recent developments of key Durable Medical Equipment Rental providers are as follows:

In June 2020, MedOne Company announced the launch of a new facility in North Carolina. U.S., for the rental and service of medical equipment.
In March 2020, Med-Equip announced the acquisition of Martab’s equipment management services. The acquisition is being carried out to provide rentals of custom-made gadgets such as home testing kits.

Market Segments Covered in Global Durable Medical Equipment Rental Industry Analysis

By Application:

Personal Mobility Devices
Bathroom Safety and Medical Furniture
Monitoring and Therapeutic Devices

By End Use:

Personal/Homecare
Institutes and laboratories
Hospitals

Explore In-Depth Market Research: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16401

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Electronic Toll Collection Market Projected to Reach US$ 34.26 Billion by 2033

It was estimated that the electronic toll collecting market sector will bring in a total of around US$11.43 billion by the end of 2022. International demand for electronic toll collection systems is anticipated to grow at a compound annual growth rate (CAGR) of 10.6% between 2023 and 2033. It is anticipated that the size of the worldwide electronic toll collection market would rise from US$12.46 billion in 2023 to US$34.26 billion by 2033.

The need for efficient and seamless toll-collection systems has grown dramatically in recent years, driving the growth of the ETC systems market. ETC systems provide autonomous toll collection without requiring manual transactions by utilising state-of-the-art technologies such as RFID-based toll systems and dedicated short-range communication.

Request our market sample report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-76

The overall market’s expansion is hampered by the high initial set-up expenses as well as the large running and maintenance expenditures. The expansion is also limited by the absence of standardization in toll-collecting technologies and the government’s stringent regulations for approval of electronic tolling technology.

Key Takeaways from the Electronic Toll Collection Market Analysis:

Between 2023 and 2033, the United States electronic toll collection market is forecasted to grow at an 11% annual growth rate.
Germany is the leading country in Europe for the production of electronic toll collection devices, and the regional market could witness an 8% CAGR through 2033.
The demand for electronic technology in the United Kingdom is growing at 7.5% CAGR, and it might continue till 2033 end.
China’s electronic toll collection system market dominates Asia and is estimated to progress at a lucrative 9.5% CAGR from 2023 to 2033.
India is a remarkably growing market for automated tolling collection systems and is expected to exhibit a robust 12.2% CAGR through 2033.
Based on technology type, the electronic toll collection systems with RFID are expected to garner 28.7% of the global revenue share in 2023.

Electronic Toll Collection Market Competitive Landscape:

The overall market is fairly consolidated, as a few market layers hold a sizable portion of the global market. Numerous important developments are taking place in the ETC industry as cashless tolling systems have become more popular since the pandemic. Contactless payment for tolls is convenient, lessens traffic, improves overall road safety, and is anticipated to provide government support for the establishment of new players.

Recent Developments by the Market Players:

The Thousand Islands Bridge Authority chose TransCore in June 2022 to create, implement, and operate its newly installed next-generation toll-collecting systems. The conventional system at this international bridge connecting New York with Wellesley was replaced with TransCore advanced toll collection devices and systems.
At the Intelligent Transport System World Congress in October 2021, innovative electronic tolling automation was jointly introduced by AEye Incorporate and Intetra. By enhancing AEye’s 4Sight M LiDAR features, the firms made high-resolution detection possible in toll booths. The high-performance LiDAR solution provided by AEye recognizes different kinds of vehicles, their speeds, traffic, and environmental factors.

Purchase the Report for Market-Driven Insights:
https://www.futuremarketinsights.com/checkout/76

Electronic Toll Collection Market Segmentation:

By Product Type:

Transponders
Antennae
Communication systems
Treadles
Inductive loops
Scanning devices
Weigh-in-motion devices
Cameras and film storage devices

By Technology Type:

Radio-Frequency Identification (RFID)
Dedicated Short-Range Communications (DSRC)
Video Analytics
Global Navigation Satellite System (GNSS)
Global Positioning System (GPS)

By Application Type:

Highway
Urban
Bridges

By Region:

North America Market
Latin America Market
Asia Pacific Market
Japan Market
Western Europe Market
Eastern Europe Market
Middle East & Africa (MEA) Market

Author:

Sudip Saha is the managing director and co-founder at Future Market Insights, an award-winning market research and consulting firm. Sudip is committed to shaping the market research industry with credible solutions and constantly makes a buzz in the media with his thought leadership. His vast experience in market research and project management a consumer electronics will likely remain the leading end-use sector cross verticals in APAC, EMEA, and the Americas reflects his growth-oriented approach to clients.

He is a strong believer and proponent of innovation-based solutions, emphasizing customized solutions to meet one client’s requirements at a time. His foresightedness and visionary approach recently got him recognized as the ‘Global Icon in Business Consulting’ at the ET Inspiring Leaders Awards 2022.

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Thrombocytopenia Treatment Market Set to Surge, Projected to Reach US$ 10 billion by 2033 at a 5.2% CAGR

Global Thrombocytopenia Treatment Industry

The Global Thrombocytopenia Treatment Market, for thrombocytopenia therapy will grow at a compound annual growth rate (CAGR) of 5.2% between 2023 and 2033. The industry is expected to increase in valuation from US$ 6 billion in 2023 to US$ 10 billion in 2033. The global market for thrombocytopenia treatment is being driven by a number of factors, including increased awareness of thrombocytopenia and its treatment, cheap thrombocytopenia therapy, and higher rates of thrombocytopenia morbidity and death.

This forecast heralds a revolution in the field of therapy, particularly in Korea where the creation of new medications is anticipated to fundamentally alter the way thrombocytopenia is treated. The most popular treatment option at the moment is platelet transfusions; however, there are disadvantages to this approach, including the risk of infection and other problems.

The development of new medications like eltrombopag, romiplostim, and eltrombopag heralds a revolutionary era for patients with thrombocytopenia. These innovative treatments offer a compelling combination of lower risks and higher efficacy, putting them in a position to overcome the drawbacks of conventional methods.

In a similar vein, doctors may more easily diagnose patients accurately and begin appropriate treatment at an early stage because to the availability of these drugs. The timely identification and management of thrombocytopenia are essential as they might mitigate chronic problems and enhance the prognosis of patients. Additionally, a variety of therapy choices customized to meet the specific needs of each patient are offered by these new drugs.

Request a Sample of this Report Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16395

The development of novel cost-effective treatments is also expected to increase access to thrombocytopenia treatment in Korea. Patients with thrombocytopenia often have difficulty getting treatment due to lack of resources or cost barriers, but with the introduction of affordable medications, people will have access to the care they need.

The government of Korea is providing financial support to its citizens to help them access the best treatment available. This is not only beneficial to patients but also provides an incentive for healthcare providers to use the most up-to-date treatments

These initiatives are expected to play a significant role in driving the demand for advanced treatments for thrombocytopenia in Korea. By providing financial support and incentives, governments can ensure that patients have access to the most effective treatments available and that healthcare professionals are using the best technologies available. This, in turn, will drive demand for advanced treatments for thrombocytopenia and help improve patient outcomes.

Overall, the introduction of safe and efficient medication will drive growth in the thrombocytopenia treatment market in Korea. With increased availability of treatments and improved outcomes, people will be able to access the care they need and lead healthy lives.

Key Takeaways from the Global Thrombocytopenia Treatment Industry

The global thrombocytopenia treatment market is anticipated to surpass US$ 6 billion in 2023.
By 2033, a massive valuation of US$ 10 billion has been predicted by Future Market Insights for the global thrombocytopenia treatment market.
Korea’s thrombocytopenia treatment market is anticipated to account for a significant valuation by the end of 2033.
Introduction of safe, efficient, and affordable medication and increasing government support are likely to provide an impetus to Korea’s thrombocytopenia treatment market.

“Development of safe, affordable, and efficient medication coupled with favorable government schemes will provide an opportunity for market expansion in Korea. Hence, key companies are engaging in research and development practices to increase their market presence.”– Says an FMI Analyst.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16395

Competition Landscape in the Global Thrombocytopenia Treatment Industry

To gain a significant market position, key companies are investing in research and development practices to develop novel methods and treatments. In addition, these companies are also joining hands with online pharmacies to make their products available globally.

Novartis Korea, Karyopharm Therapeutics Inc, and InnnoCare are apex companies in Korea’s thrombocytopenia treatment market.

Recent Developments:

In December 2022, Karyopharm Therapeutics Inc., a promotional pharma business developing innovative cancer treatments, confirmed recently updated Phase 1 findings from its research investigating the safety and effectiveness of once-weekly selinexor in conjunction with standard dosage ruxolitinib in individuals with medicine myelofibrosis (NCT04562389).
In May 2018, Revolade, manufactured by Novartis Korea, was officially approved to treat severe aplastic anemia in patients who have not responded well to immunosuppressive medication. As a result of the bone marrow’s inability to make enough blood cells for the body, people with severe aplastic anemia have symptoms including exhaustion, dyspnea, and unusual bleeding or bruises.

Anticoagulant therapy depends on the underlying cause of the condition. Some of the common treatments for thrombocytopenia include:

Treating the underlying cause: If the thrombocytopenia is caused by an underlying medical condition such as a viral infection, treating the condition can help improve platelet count.
Medications: In some cases, medications such as corticosteroids, immune globulin, or thrombopoietin receptor agonists may be prescribed to help increase platelet count.
Platelet transfusion: If a person has a very low platelet count and is at risk of bleeding, a platelet transfusion may be necessary to help prevent bleeding.
Surgery: If thrombocytopenia is caused by an enlarged spleen, surgery to remove the spleen may be recommended.
Lifestyle modifications: Avoiding activities that increase the risk of bleeding, such as contact sports, can help reduce the risk of bleeding in people with thrombocytopenia.

It is important to work with a healthcare professional to determine the best treatment plan for thrombocytopenia based on the individual’s specific circumstances.

Click Here To Buy Your Full Report:
https://www.futuremarketinsights.com/checkout/16395

Key Segments Profiled in the Global Thrombocytopenia Treatment Industry Survey

By Drug Class:

Glucocorticoids
Lysosomal Enzyme
Platelet Stimulating Agent

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Global Chronic Smell and Flavor Loss Treatment Market Continues Upward Trajectory, Projected to Reach US$5,850.2 Million by 2033 at a 6.4% CAGR

Global Chronic Smell and Flavor Loss Treatment Industry — Global Chronic Smell and Flavor Loss Treatment Market

The global Chronic Smell And Flavour Market is expected to develop at a strong compound annual growth rate (CAGR) of 6.4% from its present valuation of US$3,146 million in 2023. The healthcare technology market is expected to grow significantly and reach US$5,850.2 million by 2033.

Chemosensory dysfunction, or persistent loss of taste and smell, can have a serious negative effect on a person’s quality of life. This press release can be customized for a business that is creating novel therapies, one that offers diagnostic equipment, or one that works to increase public awareness of taste and smell issues.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16370

The development of conditions-specific therapies for chronic loss of flavor and odor will facilitate market expansion. PDE inhibitors, for instance, are present in CYR-064 formulations and are meant to be administered intranasally. All diseases causing a loss of scent and taste share a common basic mechanism. It includes blocking the activation of stem cells, which is often caused by adenylyl cyclase III acting through cAMP and cGMP.

North America dominates the market for therapies for chronic smell and flavor loss due to the presence of large firms in the sector, the introduction of innovative products, and a strong healthcare system that will support market expansion in the region. Europe’s significant R&D investments are helpful for market growth.

The producers have a greater role in the creation of treatments for persistent odor and flavor loss. Additionally, ingenuity and research are done to introduce novel items for treating persistent odor and flavor loss.

Key Takeaways from the Market Study:

As of 2023, the chronic smell and flavor loss treatment market was valued at US$ 3146 Million
From 2023 to 2033, the chronic smell and flavor loss treatment industry is poised to grow at an 6.4% CAGR
By 2033, the chronic smell and flavor loss treatment market is slated to reach a valuation of US$ 5850.2 Million
China is poised to yield a CAGR of 6.0% with respect to chronic smell and flavor loss treatment in 2033

“Growing healthcare spending and increase in the prevalence of smell disorders and taste disorders are expected to radically transform the chronic smell and flavor loss treatment market in the coming years,” comments an analyst at FMI.

Competitive Landscape:

Some of the key players in the chronic smell and flavour loss treatment market like Cyrano Therapeutics, Johns Hopkins, Boys Town National Research Hospitals, MSD Manual, Alcon, Stanford Medicine, Immunomic Therapeutics, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, HYCOR Biomedical, Inc. and others.

The manufacturers are involved in the production of chronic smell and flavour loss treatment in a larger capacity. Research and innovation are also conducted to launch innovative products for chronic smell and flavour loss treatment.

Cyrano Therapeutics has developed a nasal spray to treat and restore the sense of smell and flavor in those who have experienced a chronic loss of those senses.The Company was founded by an experienced healthcare executive after personally experiencing a chronic loss of smell and flavor. The nasal spray has restored his smell and flavor function and he is now leading a mission to bring it to others.
Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16370

Key Segments Covered in Chronic Smell and Flavor Loss Treatment Industry Survey:

Chronic Smell and Flavor Loss Treatment Market by Classification:

Smell Disorder
Taste disorder

Chronic Smell and Flavor Loss Treatment Market by Symptoms:

Anosmia or Hyposmia
Dysgeusia
Ageusia

Chronic Smell and Flavor Loss Treatment Market by Taste Type:

Self-Assessment Test
Psychophysical Assessment Test
Imaging Test
Other Tests

Chronic Smell and Flavor Loss Treatment Market by Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific
Middle East and Africa(MEA)

Unlock In-Depth Market Trends: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16370

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Intestinal Fistula Treatment Market Set to Flourish, Expected to Reach US$46.82 Billion by 2033 at a 5.8% CAGR

Global Intestinal Fistula Treatment Industry

The global Intestinal Fistula Treatment Market is projected to reach US$46.82 billion by 2033. This represents a noteworthy increase from 2023’s value of US$26.64 billion, indicating a 5.8% compound annual growth rate (CAGR) throughout the projection period (2023-2033).

The intestinal fistula treatment market is expected to grow during the course of the forecast period due to factors including the rising prevalence of ulcerative colitis and Crohn’s disease as well as improved awareness of the ailment globally. Several significant industry companies are focusing on research and development in addition to exploring new and potential avenues for the treatment of intestinal fistulas.

Preview Next-Level Insights Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16376

For instance, phase 3 clinical trials conducted by Eli Lilly and Company evaluated the long-term safety and effectiveness of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. It is consequently anticipated that this will quicken market expansion during the projection period.

Furthermore, the increasing need for biologics to address a range of illnesses has compelled industry players to expand their product portfolios and market their goods globally. Thus, it is also expected that in the near future, the market would expand due to rising patient preferences for prescriptions and a rise in regulatory approvals for the pharmaceuticals offered by the key companies. Increased awareness of intestinal fistula therapy and an increase in hospitalization instances for the disease are the primary factors expected to propel market expansion. An NCBI article from 2020 states that there are nine to twenty instances of ulcerative colitis for every 100,000 persons annually.

Key Takeaways from the Market Study

Global intestinal fistula treatment market was valued at US$ 25.18 Billion by 2022-end
From 2018 to 2022, the market demand expanded at a CAGR of 2%
By drug class, proton-pump inhibitors to yield 45% revenue in the global intestinal fistula treatment market
By distribution channel, the hospital pharmacies segment dominates the market with a share of 46%
From 2023 to 2033, intestinal fistula treatment worth is expected to flourish at a CAGR of 8%.
By 2033, the market value of Intestinal Fistula Treatment is expected to reach US$ 82 Billion

“An upsurge in financial support to researchers for developing new innovative drugs for treatment of intestinal fistula, coupled with increasing prevalence of Crohn’s disease are expected to fuel the Intestinal Fistula Treatment Market in the forthcoming years,” remarks an FMI analyst.

Competitive Landscape

Livealth BioPharma
Boehringer Ingelheim International GmbH
Pfizer Inc.
Apsolabs
AstraZeneca
Pipelinepharma
Astellas Pharma Inc.
Caspian Tamin Pharmaceutical Company
Eli Lilly
GlaxoSmithKline
Bristol-Myers Squibb
Merck & Co. KGaA
Moderna Inc.

Recent Developments:

In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and the patient outcomes with brazikumab.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16376

Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis

By Drug Class:

Anticholinergic
Proton-Pump Inhibitors
H2 Blockers
Antidiarrheals

By Route of Administration:

Oral
Parenteral
Rectal
Transdermal
Intravenous

By Distribution Channel:

Hospital Pharmacies
Clinical Pharmacies
Drug Stores
Online Pharmacies

Obtain Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16376

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Andersen-Tawil Syndrome (ATS) Treatment Market Poised to Reach US$4.2 Billion by 2033, Reflecting a Compelling Growth Trajectory with a 8.26% CAGR

The global Andersen-Tawil syndrome (ATS) treatments market is expected to reach an impressive valuation of US$4.2 billion by 2033. From an astounding US$1.9 billion in 2023, this is a significant increase, with a strong compound annual growth rate (CAGR) of 8.26% anticipated for the forecast period.

Data on the Andersen-Tawil syndrome has become easily accessible on a global scale in recent years, which has helped the market and related research activities grow. The need for medications for Andersen Tawil syndrome is also being fueled by an increase in government funding and incentives for research on uncommon diseases. In addition, future developments will benefit from the growing involvement of public and private groups that support treatment and raise awareness.

Get Latest Sample Copy:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16357

However, a major issue still impacting market participants is the low prevalence of the Andersen-Tawil syndrome and lack of awareness. High misinterpretation rates and undiagnosed patients remain major obstacles to the industry’s expansion. Furthermore, progress will be hampered by the high expenses of researching rare diseases, which will impede innovations and growth opportunities.

A few other factors also hinder the growth of the global market: difficulties in research and development; delays in diagnosis leading to treatment delays; limitations in terms of expertise; a general lack of economic attractiveness that ultimately results in a lack of private investors’ commercial interest; and a lack of regulatory framework in developing economies combined with a shortage of skilled healthcare personnel.

Key Takeaways

Increasing focus of the government to prioritize drugs for the treatment of rare diseases are expected to propel growth
Increasing participation of organizations to support the treatment and to create awareness is also anticipated to drive growth of the market.
Growth in R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to aid in market expansion.

North America is expected to dominate the market of Andersen Tawil syndrome.
South Asia is projected to witness fastest growth during the forecast period.
Type 1 Andersen Tawil Syndrome is projected to dominate the market with 59% market share by 2033.

“Increased government funding efforts aimed towards improving diagnostic procedures is anticipated to generate lucrative prospects for the participants in the Andersen-Tawil syndrome market. Non-profit organizations are playing key roles in raising awareness positively influencing market developments”, comments an FMI analyst.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16357

Competitive Landscape

Key players in the Andersen Tawil Syndrome Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc., and Pfizer Inc.

Some recent developments in this market are:

In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
In December 2016, Strongbridge Biopharma plc has acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of agreement, Taro Pharmaceutical Industries Ltd to receive an upfront payment of USD 8.50 mm and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of U.S. rights expands company’s rare disease portfolio to include neuromuscular diseases.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Disease type (Type 1, Type 2) By Drug class (Carbonic Anhydrate Inhibitors, Acetazolamide, Dichlorpenamide, Antiarrhythmic Drugs, Amiodarone, Flecainide, Beta-Blockers, Atenolol) By Distribution channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) and by region (North America, Latin America, Europe, South Asia, East Asia, Oceania MEA)

Key Segments Profiled in the Andersen Tawil Syndrome Treatment Market Industry survey

Disease Type:

Type 1
Type 2

Drug Class:

Carbonic Anhydrate Inhibitors
Acetazolamide
Dichloropenamide
Antiarrhythmic Drugs
Amiodarone
Flecainide
Beta-Blockers
Atenolol

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Explore In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16357

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Physical Security Market Sees Strong Growth: Valuation Expected to Reach $229.11 Billion by 2032

During the forecast period of 2022–2032, the physical security market is anticipated to expand gradually at a value CAGR of 6.3%. This market was anticipated to have a global market valuation of US$ 117 billion earlier in 2021 and is anticipated to reach US$ 229.11 billion by 2032.

Physical security methods are used to protect equipment and structures. To keep technology and data secure, physical security breaches and dangers must also be avoided in addition to network and cyber security. The workers and professors who have access to the building likewise hold this to be true.

The structure is safeguarded against natural disasters, vandalism, fire, theft, and terrorism. Multiple layers of interconnected systems, CCTV surveillance, security guards, locks, and access control comprise the system.

From 2017 to 2021, the physical security industry grew at a CAGR of 5.9%. Global physical security market growth has been boosted by an increase in terror attacks and an increase in awareness. Moreover, technological advancements have also contributed to the growth of the physical security market.

Get a Sample Copy of Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14992

Physical security market growth, however, is hindered by privacy concerns and lack of integration between physical and logical security. On the other hand, the escalating demand for security in smart cities is likely to offer lucrative opportunities for the expansion of the physical security market during the forecast period.

North America is expected to maintain its leadership position in the physical security industry during the forecast period, owing to a rise in the adoption of physical security solutions across critical infrastructures such as nuclear power plants, chemical plants, and oil and gas facilities across the region. However, Asia-Pacific is expected to be one of the fastest growing regions during the forecast period, driven by a high demand for physical security solutions and an increase in terror attacks.

Key Takeaways from the Market Study

In 2022, the global physical security market is estimated to have a global market size of US$ 124.37 Billion.
The physical security market in North America acquired 39% of the global market share in 2021.
The APAC region is expected to grow with a 5.5% CAGR during 2022-2032.
The systems segment took over 66% of the global physical security market share in 2021.
The market was dominated by the SMEs segment in 2021 and a 8.5% CAGR is expected during 2022-2032.
The residential segment is projected to exhibit a 7% CAGR during 2022-2032.

Competitive Landscape

To gain a larger share of the market, top companies provide diverse solutions to address a range of applications. Moreover, companies seek to increase their market share by merging, acquiring, and forming strategic alliances. The company pursues a variety of strategic initiatives to achieve its goals, including partnerships, mergers, acquisitions, collaborations, and new product development. They offer systems and services to a wide range of industries.

Immersal-Part of Hexagon, which develops visual positioning systems and mapping software, has been acquired by Hexagon AB. in July 2021. A leader in PKI solutions, DigiCert, Inc., has partnered with Johnson Controls to provide advanced, digital, physical security solutions to buildings in May 2021.
Hangzhou Hikvision Digital Technology Co., Ltd. released its Hikvision AX PRO wireless external tri-tech detector and dedicated camera in February 2022.
An Edge360 security solutions provider partnered with Quanergy Systems, Inc., an AI-enabled LiDAR platform, in 2022. Edge360 will be able to provide video surveillance based on LiDAR technology in residential buildings and financial institutions as a result of this partnership.

Get expert answers at your fingertips – Ask an Analyst today!
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-14992

Key Segments Covered in the Physical Security Market Report

Physical Security Market by Component Type:

Physical Security Systems
- Physical Access Control System (PACS)
- Perimeter Intrusion Detection and Prevention
- Video Surveillance System
- Physical Security Information Management (PSIM)
- Fire and Life Safety
- Physical Identity & Access Management (PIAM)
Physical Security Services
- Remote Monitoring
- System Integration
- Others
Other Physical Security Components

Physical Security Market by Organization Size:

Physical Security for SMEs
Physical Security for Large Enterprises

Physical Security Market by End Users:

Physical Security for Transportation
Physical Security for Banking & Finance
Physical Security for Government
Physical Security for Utility & Energy
Physical Security for Industrial Use
Physical Security for Residential Use
Physical Security for Retail
Physical Security for Hospitality
Physical Security for Commercial Use
Physical Security for Other End Users

Physical Security Market by Region:

North America Physical Security Market
Europe Physical Security Market
Asia Pacific Physical Security Market
Middle East & Africa Physical Security Market
Latin America Physical Security Market

Tailored insights for you – Discover our Report Customization feature!
https://www.futuremarketinsights.com/customization-available/rep-gb-14992

Author:

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Surimi Market Positioned for US$ 6,548 Million Valuation by 2033 with a 6.1% CAGR, Predicts Future Market Insights

According to Future Market Insights (FMI), the global surimi market is set to be valued at US$ 3,572.7 million in 2023. Over the next decade (2023 to 2033), global surimi demand is likely to rise at 6.1% CAGR. By 2033, the total market valuation is forecast to reach US$ 6,548.3 million.

Increasing demand for protein-based food products is a key factor that will drive the global surimi industry.

People are becoming aware of the advantages of eating nutritious foods and living healthy lifestyles. Health-conscious consumers prioritize weight management and exercise to reduce the chance of health problems and disorders such as cholesterol levels, diabetes, blood pressure, and heart disease.

Various health-conscious consumers concentrate solely on exercise and fail to consume enough protein, resulting in a variety of deficiencies. To prevent deficits and keep healthy lifestyles, they are consuming more protein-based products such as surimi than calorie-based products.

Find more insights in a sample report: https://www.futuremarketinsights.com/reports/sample/rep-gb-17160

Increasing consumption of surimi due to its protein-rich nature is expected to boost the global surimi industry during the projection period.

The adoption of innovative manufacturing technologies to boost surimi production will positively impact market development.

Apart from the United States and Europe countries, surimi is a widespread ingredient in other emerging markets. Countries such as India offer lucrative opportunities for manufacturers of surimi due to the presence of recognized surimi brands such as Grande Marine.

Various manufacturing technologies such as high-pressure processing, ultrasonic processing, enzyme-assisted processing, and microwave-assisted processing are being used by companies. This in turn is helping in boosting the market.

In India, there is increasing demand for surimi products such as surimi flakes, crab sticks, and surimi fish sticks in the retail market. Sales of small package sizes and ‘grab and go’ convenience items have surged.

Surimi allows manufacturers to imitate the texture and taste of more expensive products, such as lobster tails, by using less-expensive materials. The growing usage of surimi for making various kinds of high-nutritional processed foods is expected to boost the market.

Affordability is a considerable factor in increasing retail sales of surimi. Consumers have noted that surimi is just one-third the price of other seafood. It is a low-cost source of protein that is simple to incorporate into seafood meals by individuals cooking at home.

Key players are investing in research & development to create new varieties with innovative characteristics. New high-quality products with sustainable packaging are being introduced into the market to meet the changing consumer demand.

For instance,

In December 2022, to decrease the amount of plastic and increase recyclability, Mondi gave Angulas Aguinaga supplementary packaging. It was made of recyclable paper for its Krissia brand chilled surimi sticks.
In September 2020, the Japanese seafood company, Maruha Nichiro, introduced a new line of surimi-based products called “Crab Tsumami”. These are made with a combination of real crab meat and surimi paste.

“Growing consumer awareness surrounding organically-sourced foods is a major trend driving growth for surimi products. Manufacturers are likely to find significant growth opportunities in crafting products that are affordable, offer various flavors, and are available in compact packs for instant consumption.” – says a lead analyst at Future Market Insights (FMI)

Request for Report Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-17160

Key Takeaways from the Report:

Global demand for surimi is projected to rise at 6.1% CAGR during the assessment period.
By species, the fish surimi segment is anticipated to hold about 84.55% share of the global market.
Based on form, the fresh category is likely to top a valuation of US$ 2,220.2 million by the end of 2023.
The United States surimi market is expected to reach a valuation of US$ 568.2 million by 2033.
East Asia is projected to account for about 51.0% share in the surimi market by 2023.
China’s surimi industry is projected to reach a valuation of US$ 1,888.7 million.

Who is Winning?

Trident Seafoods, Aquamar Inc, American Seafoods Group, Maruha Nichiro Group, Russian Fishery Company, Viciunai Group, Seaprimexco Vietnam, Trans-Ocean, Thong Siek Global, Gadre Marine, Glacier Fish Company, Ocean More Foods Co., Limited, A B Golden Seafood, Arctic Storm Management Group, Maruha Nichiro Group, Seapack Food, Russian Fishery Company, and Trans-Ocean Products are few of the key manufacturers of surimi profiled in the report.

These companies are constantly upgrading their portfolios by launching new surimi varieties. They are also adopting a merger & acquisition strategy as well as forming alliances and partnerships to expand their presence. For instance,

Recently, new surimi-eel dishes were introduced by Angulas Aguinaga for young customers.
In January 2023, Santa Bremor announced that it will relocate the production of surimi sticks to its Russian Sea plant in Noginsk.

Get More Valuable Insights into Surimi Market

Future Market Insights (FMI), in its offering, provides an unbiased analysis of the surimi market by presenting historical data between 2018 and 2022 and forecast statistics for the period from 2023 to 2033.

The study divulges compelling insights on the surimi market based on species (fish surimi (Alaska pollock, Atlantic cod, tilapia, black bass, others)) and (meat surimi (pork, beef)), form (fresh (whole, filet)) and processed (canned, frozen (whole and filet)), sales channel (direct sales and indirect sales (modern trade, convenience stores, speciality food stores, wholesale stores, discount stores, online retail, other retail formats)), and application (food industry, pharmaceutical industry, animal feed, pet food, food service, retail) across prominent regions.

Didn’t find the data you are looking for? Our experts provide you with customized reports: https://www.futuremarketinsights.com/customization-available/rep-gb-17160

Surimi Market Outlook by Category

By Species:

Fish Surimi
Alaska Pollock
Atlantic Cod
Tilapia
Black Bass
Others
Meat Surimi
Pork
Beef

By Form:

Fresh
Whole
Fillet
Processed
Canned
Frozen
Whole
Fillet

By Sales Channel:

Direct Sales
Indirect Sales
Modern Trade
Convenience Stores
Speciality Food Stores
Wholesale Stores
Discount Stores
Online Retail
Other Retail Formats

By Application:

Food Industry
Pharmaceutical Industry
Animal Feed
Pet Food
Food Service
Retail

By Region:

Latin America
North America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact FMI:

Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube